middle.news
How Will ReNerve’s Expanded Hong Kong Approval Boost NervAlign® Sales?
9:29am on Monday 12th of January, 2026 AEDT
•
Healthcare
Read Story
How Will ReNerve’s Expanded Hong Kong Approval Boost NervAlign® Sales?
9:29am on Monday 12th of January, 2026 AEDT
Key Points
Broader Hong Kong market access including Greater Bay Area hospitals
Independent regulatory review confirms safety and effectiveness
NervAlign® Nerve Cuff marketed in five countries, pursuing 10+ more
FY25 revenue growth of 53%, reaching $271k in sales
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Renerve (ASX:RNV)
OPEN ARTICLE